Talphera (TLPH) Q3 2026 Earnings Call Transcript
Talphera (TLPH) reported Q3 2026 earnings, seeking FDA approval to conclude Niyad enrollment early due to 80% statistical power. They increased peak U.S. sales estimate to over $200M. Cash balance was $14.2M, with $16M in potential financing. Operating expenses rose to $3.8M from $3.3M YoY. Enrollment challenges were discussed, with no clear cause identified.
How this was made

The 30-second read
Why it matters
The company seeks FDA Sprint Meeting feedback and projects >$200M peak U.S. sales, indicating a sizable market opportunity.
Market read
New guidance on cash, expenses, and market potential could move TLPH stock as investors reassess valuation.
What to watch
Regulatory timeline uncertainty and competitive landscape in CRRT anticoagulation.
Background
Talphera is a medical‑device company developing Niyad, a nafamostat‑based anticoagulant for CRRT.
Ticker impact
Q3 2026 earnings call disclosed cash balance of $14.2M, increased R&D expenses, and a $200M peak sales estimate for Niyad.
potential modest upside as investors price in stronger commercial potential and sufficient cash runway
The call provides fresh guidance on sales potential and cash resources, which were not previously public.
Market effects
Highlights growth prospects for CRRT anticoagulation market and may benefit peer medical device firms.
U.S. market focus with potential FDA feedback later this year.
Limited to niche medical device sector; no broad macro impact.
Counterpoint
If enrollment delays persist, the sales outlook may be overly optimistic.
Key entities
- CompanyTalphera
Developer of Niyad, subject of the earnings call.
- RegulatorFDA
Target of Sprint Meeting request for Niyad's regulatory pathway.


